Text Size

Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease – a randomized controlled trial

Konstas A.-G., Boboridis K. G., Athanasopoulos G. P., Haidich A.-B., Voudouragkaki I. C., Pagkalidou E., Katsanos A., Katz L. J.

  • 2023
  • Eye
View publication
  • Therapeutic Area


  • Categories

    Clinical development

  • Affiliations

    University Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Epidemiology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Ophthalmology, University of Ioannina, Ioannina, Greec; Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA

Related Publications

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

Magnetically actuated glaucoma drainage device for regulating intraocular pressure after implantation

Pereira ICF, van Mechelen RJS, Wyss HM, Pinchuk L, Beckers HJM, den Toonder JMJ.

Latanoprost incorporates in the tear film lipid layer: An experimental and computational model study

Riedlová K, Saija MC, Olżyńska A, Vazdar K, Daull P, Garrigue JS, Cwiklik L.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022